Can a common heartburn pill change how a cancer drug works?

NCT ID NCT07742384

Not yet recruiting Knowledge-focused Sponsor: Nuvation Bio Inc. Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This study in healthy adults tests whether famotidine, a common heartburn medication, changes how the body absorbs and processes taletrectinib, an experimental cancer drug. Participants receive taletrectinib alone or with different doses and timings of famotidine to compare drug levels in the blood. The goal is to understand if these two drugs can be taken together safely and without affecting taletrectinib's effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: taletrectinib and famotidine
What this could lead to: If famotidine does not significantly alter taletrectinib levels, it could allow patients taking both to do so without dose adjustments, improving convenience and adherence.
What could go wrong: This is an early-phase study in healthy volunteers, not patients, so results may not fully predict effects in people with cancer. Also, famotidine might reduce taletrectinib absorption, which could complicate co-administration.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY ADULT PARTICIPANTS

More trials for these conditions

Other studies related to the condition(s) this trial covers.